Sanofi-Aventis, Astellas to restructure Japan JV, rights to products rejiggered |
|
|
|
Published
:
Fri, 30 Nov 2007 07:40 |
PARIS (Thomson Financial) - Sanofi-Aventis and Astellas Pharma will restructure their Japanese joint venture FSA, with the result that Sanofi-Aventis will get certain rights to insomnia drug Myslee while the venture's other drugs, notably Primperan, Dogmatyl and Gramalil, will be sold exclusively by Astellas, Sanofi-Aventis said.Myslee will continue to be promoted by both companies and distributed by Astellas.tfn.paris@thomson.commjs/sljCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|